News for WuXi AppTec Co., Ltd. (603259.SS)

The following slide deck was published by WuXi AppTec Co., Ltd.

Summary Wuxi AppTec Co Ltd (WUXAY), a global leader in R&D and manufacturing services for the pharmaceutical and life sciences industries, announced its financi

PR NewswireSHANGHAI, April 28, 2025 Total Revenue Reached RMB9.65 Billion, Up 21.0% Year-over-Year; among which Revenue from Continuing Operations Reached

Wuxi AppTec Co Ltd (WUXAY), a global leader in R&D and manufacturing services for the pharmaceutical and life sciences industries, announced its financial resul

PR NewswireSHANGHAI, March 17, 2025 Fourth-Quarter Revenue Reached RMB11,539 Million, Up 6.9% Year-over-Year2024 Revenue Reached RMB39,241 Million, Up 5.2%

Summary Wuxi AppTec Co Ltd (WUXAY), a leading global provider of R&D and manufacturing services for the pharmaceutical and life sciences industries, announced o

Wuxi AppTec Co Ltd (WUXAY), a global leader in R&D and manufacturing services for the pharmaceutical and life sciences industries, announced on December 30, 202

Wuxi, China biotech stocks surge on hopes of less severe US sanctions

Asian stocks rise with inflation in focus; China dips on US jitters

Key Takeaways: U.S. sales dipped slightly, with limited impact for now from a proposed law that could limit Chinese access to the U.S. drugs market, where WuXi AppTec makes nearly two thirds of its revenue China’s drug services companies are cutting prices in a battle for business, eating into profit margins

China’s Wuxi AppTec, Biologics, tumble as US sanctions threat grows

China's WuXi AppTec, Wuxi Biologics plunge to multi-year lows on fears over US biotech bill

The rise in the prevalence of diseases & disorders and growth in government & organizational investments to develop APIs are major contributors to the...

Global cell and gene therapy manufacturing services market is growing at a CAGR of 17.1% during 2022–2030....

/PRNewswire/ -- The

The global contract research organization (CRO) services market is anticipated to depict a 12.1% CAGR through the estimated period. Crucial factors...

/PRNewswire/ -- The

Revenue of the Cell Line Development Industry is set to reach US$ 8.2 Billion by 2033-End...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing.